Medivation BANKING on Cancer Treatment and 4 New Analyst Insights

| + More Articles
  • Like on Facebook
  • Share on Google+
  • Share on LinkedIn

Cabot Corp. (NYSE:CBT): Buckingham currently sees Cabot at buying levels and believes the profitability of the Norit acquisition is being underestimated. Shares have a Buy rating and a $56 price target.

Don’t Miss: Facebook Facing BACKFIRE Over New Business Move?

Medivation, Inc. (NASDAQ:MDVN) has had its target increased by William Blair following the firm’s increase on its estimate of Medivation’s enzalutamideprostate cancer treatment’s selling price. The firm raised the selling price estimate because of the superior data of the drug in comparison with its competitor. The firm keeps an Outperform rating on the stock.

McCormick & Co. Inc. (NYSE:MKC) price target was increased by KeyBanc ahead of results for Q2. The firm noted the moderation of historically high commodity cost inflation and accretion from recently made deals. This should cause a resumption of earnings growth. Shares hold a Buy rating.

AGCO Corporation (NYSE:AGCO): According to Wells Fargo, the USDA Crop Progress reports suggests the conditions for both corn and soybean crops have become worse. This coupled together with forecasts for more hot, dry weather could be positive for crop commodity prices as well as Ag equipment names.

Sequenom Inc. (NASDAQ:SQNM) could accession over 25,000 tests during Q3, beating Street expectations, William Blair says after conducting checks. The firm predicts appreciation in the stock and maintains its Outperform rating on the shares.

Don’t Miss: Use a Mac? Orbitz Will Send You to A Pricier Hotel.

Want news like this in real-time so you can get an edge? Click here for Wall St. Cheat Sheet Pro.

More Articles About:

To contact the reporter on this story: staff.writers@wallstcheatsheet.com To contact the editor responsible for this story: editors@wallstcheatsheet.com

Yahoo Finance, Harvard Business Review, Market Watch, The Wall St. Journal, Financial Times, CNN Money, Fox Business